Therapeutic area intelligence for Radiopharmaceutical with 4 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals: 4
Catalysts: 0
Companies: 2

Companies

CARDIOGEN-82 →

Novartis →

Assets

Recent signals(4)

RegulatoryAugust 2, 2026

FDA Approves Lutetium Lu 177 VIPIVOTIDE for Metastatic Prostate Cancer

The FDA has approved lutetium Lu 177 vipivotide tetraxetan (Pluvicto) for use in combination with androgen receptor pathway inhibitors in adults with PSMA-positive metastatic prostate cancer.

Regulatory

July 16, 2026

FDA Approves Gallium Ga-68 Gozetotide for Diagnostic Use

The FDA has approved the application ANDA219189 for Gallium Ga-68 Gozetotide, submitted by IONETIX.

RegulatoryJuly 16, 2026

FDA Accepts Supplement for CARDIOGEN-82 by BRACCO

The FDA has accepted a supplemental application for CARDIOGEN-82, a radiopharmaceutical used in cardiac imaging.

RegulatoryJune 21, 2026

FDA Grants Approval for Gallium Ga-68 Gozetotide (ANDA216410)

The FDA has granted approval for the ANDA216410 application for Gallium Ga-68 Gozetotide submitted by Radiomedix.

Upcoming catalysts

No catalysts indexed for this entity yet.

Indications

No related entities indexed yet.

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.